Genmab’s Rinatabart Sesutecan Continues Success in Advanced Ovarian Cancer Clinical Trials
New data from the Phase II RAINFOL-01 study shows rinatabart sesutecan (Rina-S), an investigative antibody-drug conjugate, demonstrated a confirmed objective response rate of 55.6%.
Genmab has shared positive results from the Phase I/II RAINFOL-01 clinical trial showing that its rinatabart sesutecan (Rina-S), an investigational folate receptor-alpha (FRα)-targeted, TOPO1 antibody-drug conjugate (ADC), achieved an overall response rate (ORR) of 55.6% in heavily pre-treated ovarian cancer (OC) patients regardless of FRα expression levels. Additionally, 1 out of 10 patients experienced disease progression and the median duration of response (mDOR) was not reached.1
These emerging results are from the B1 cohort of the trial, which is a dose expansion study in patients with histologically or cytologically confirmed advanced OC (epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer). Participants received Rina-S 120 mg/m2 every 3 weeks with a median on-study follow-up of 48 weeks. In addition to the 55.6% ORR, the investigational ADC demonstrated a disease control rate (DCR) of 88.9%.
In the Rina-S 100 mg/m2 every 3 weeks arm, with a median on study follow-up of 46 weeks, the confirmed ORR was 22.7%, the DCR was 86.4%, and the mDOR was not reached.
In a press release, Elizabeth Lee, MD, a medical oncologist in the gynecologic oncology program at Dana-Farber, said, “The antitumor activity observed in the dose expansion cohort continues to demonstrate the potential for a much-needed treatment option for patients with PROC, who have historically had poor prognosis. I am hopeful that further exploration of Rina-S will lead to advancements in the treatment landscape.”
Judith Klimovsky, MD, executive vice president and chief development officer of Genmab, added, “The updated results reinforce the potential of Rina-S and further validate our development approach in advanced ovarian cancer. We are excited to keep moving forward with the ongoing Phase III trial, to evaluate the potential of Rina-S as a treatment option for patients facing this challenging disease.”
This most recent update from Genmab follows encouraging results of Rina-S announced in September 2024. Initially, the ADC demonstrated a confirmed ORR 50% in OC patients treated with Rina-S at the 120 mg/m2 dose once every 3 weeks.2
In a press release from the time, Lee said, “Ovarian cancer presents a significant challenge, especially for those with advanced or recurrent cases, where treatment options and prognosis are often limited. The encouraging Phase I/II data for Rina-S demonstrates the potential for future treatment options for patients. We are looking forward to additional data from tumor-specific dose expansion cohorts.”
According to Genmab, the Phase II RAINFOL-01 and Phase III RAINFOL-02 studies evaluating Rina-S at 120 mg/m2 in patients with platinum resistant ovarian cancer are actively recruiting.
References
1. Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer. News release. Genmab. March 17, 2025. Accessed March 17, 2025. https://www.businesswire.com/news/home/20250317671140/en/Investigational-Rinatabart-Sesutecan-Rina-S-Continues-to-Show-Encouraging-Antitumor-Activity-in-Patients-with-Advanced-Ovarian-Cancer
2. Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial. News release. Genmab. September 15, 2024. Accessed March 17, 2024. https://www.businesswire.com/news/home/20240913038747/en/Investigational-Rinatabart-Sesutecan-Rina-S-Shows-Promising-Anti-Tumor-Activity-as-Single-Agent-in-Heavily-Pretreated-Patients-with-Ovarian-and-Endometrial-Cancers-in-Phase-12-Clinical-Trial
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
